Hormone and Metabolic Research最新文献_第8页

Metabolic Profiling Analysis of Congenital Adrenal Hyperplasia via an Untargeted Metabolomics Strategy. 通过非靶向代谢组学策略对先天性肾上腺增生症进行代谢轮廓分析

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-01-01 Epub Date: 2024-08-12 DOI: 10.1055/a-2365-7521

Fangling Liu, Chongxin Kang, Zheng Hu, Xiaoping Luo, Wei Wu, Qiuying Tao, Quan Chi, Jing Yang, Xian Wang

{"title":"Metabolic Profiling Analysis of Congenital Adrenal Hyperplasia via an Untargeted Metabolomics Strategy.","authors":"Fangling Liu, Chongxin Kang, Zheng Hu, Xiaoping Luo, Wei Wu, Qiuying Tao, Quan Chi, Jing Yang, Xian Wang","doi":"10.1055/a-2365-7521","DOIUrl":"10.1055/a-2365-7521","url":null,"abstract":"Congenital adrenal hyperplasia (CAH) manifests as an autosomal recessive disorder characterized by defects in the enzymes responsible for steroid synthesis. This work aims to perform metabolic profiling of patients with CAH, screen key differential metabolites compared to the control group, and discover the associated metabolic pathways implicated in CAH. Serum samples obtained from 32 pediatric male patients with CAH and 31 healthy control group candidates were subjected to analysis using non-targeted metabolomics strategy using ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). A total of 278 differential metabolites were identified and annotated in KEGG. Operating characteristic curves (ROC) measurement exhibited 9 metabolites exhibiting high efficacy in differential diagnosis, as evidenced by an area under ROC curve (AUC) exceeding 0.85. Pathway analysis uncovered notable disruptions in steroid hormone biosynthesis (p <0.0001), purine metabolism and irregularities in lipid metabolism and amino acid metabolism, including tyrosine and alanine, in CAH patients. These findings demonstrate that metabolic pathways of purine, amino acid and lipid metabolism, apart from steroid hormone biosynthesis, may be disrupted and associated with CAH. This study helps provide insight into the metabolic profile of CAH patients and offers a new perspective for monitoring and administering follow-up care to CAH patients.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":"39-46"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141971009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Value of lncRNAs as a Biomarker for the Diagnosis of Gestational Diabetes: A Meta-Analysis. lncRNA作为妊娠糖尿病诊断生物标志物的价值：一项元分析

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-01-01 Epub Date: 2024-10-14 DOI: 10.1055/a-2379-1326

Yang Fan, Xin Chen, Song Yang, Hongxia Tu, Youyi Zhang, Mingyi Wang, Jingying Jiang

{"title":"The Value of lncRNAs as a Biomarker for the Diagnosis of Gestational Diabetes: A Meta-Analysis.","authors":"Yang Fan, Xin Chen, Song Yang, Hongxia Tu, Youyi Zhang, Mingyi Wang, Jingying Jiang","doi":"10.1055/a-2379-1326","DOIUrl":"10.1055/a-2379-1326","url":null,"abstract":"Gestational diabetes mellitus (GDM) is a common metabolic disorder in pregnancy and leads to serious harm to the mother and the fetus. A variety of lncRNAs play a key role in GDM. This meta-analysis was performed to explore the potential value of lncRNAs in GDM diagnosis. Articles correlated with lncRNA and GDM were screened from Embase, Medline, EBSCO, PubMed, Chinese National Knowledge Infrastructure, and WanFang databases. Summary receiver operator characteristic (SROC) was performed to evaluate the pooled area under curve (AUC). Forest plot was conducted to calculate the sensitivity, specificity, diagnostic likelihood ratio (LR), diagnostic score, and diagnostic odds ratio (DOR). Deeks' funnel plot was utilized to evaluate the publication bias. Eleven articles containing 12 tests (1060 GDM patients and 1066 controls) were included in this meta-analysis. AUC (0.89, 95%CI=0.86-0.92), sensitivity (0.84, 95%CI=0.80-0.87), and specificity (0.81, 95%CI=0.77-0.85)of the SROC curve showed a high diagnostic value of lncRNA for GDM. Positive LR (PLR 4.40, 95%CI=3.45-5.60) and negative LR (NLR 0.20, 95%CI=0.15-0.26) results indicated that the diagnosis of lncRNA for GDM had low clinical utility. Diagnostic score (3.09, 95%CI=2.62-3.57) and DOR (22.04, 95%CI=13.68-35.51) results suggested lncRNAs have good discriminative effect on GDM. Heterogeneity was significantly higher, but not induced by the subgroups. LncRNAs had high diagnostic value and good discriminative effect for GDM, but the clinical utility was not high. This meta-analysis study offers a potential target for GDM diagnosis.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":"67-74"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of Recombinant Human Parathyroid Hormone 1-34 and Vitamin K2 Combination Therapy in Postmenopausal Osteoporosis. 重组人甲状旁腺激素 1-34 和维生素 K2 联合疗法对绝经后骨质疏松症的疗效。

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-01-01 Epub Date: 2024-08-28 DOI: 10.1055/a-2371-1642

Zhuo Zhang, Kun Xia, Wentao Gong, Ruopeng Mai, Peng Liu, Zhaogang Lu

{"title":"Efficacy of Recombinant Human Parathyroid Hormone 1-34 and Vitamin K2 Combination Therapy in Postmenopausal Osteoporosis.","authors":"Zhuo Zhang, Kun Xia, Wentao Gong, Ruopeng Mai, Peng Liu, Zhaogang Lu","doi":"10.1055/a-2371-1642","DOIUrl":"10.1055/a-2371-1642","url":null,"abstract":"This study aimed to assess the efficacy and safety of a combined recombinant human parathyroid hormone 1-34 [rhPTH (1-34)] and vitamin K2 therapy versus vitamin K2 alone in the treatment of postmenopausal osteoporosis. A total of 77 postmenopausal osteoporosis patients were randomly divided into two groups. Patients in one group received vitamin K2 alone, while patients in the other group received a combination of rhPTH (1-34) and vitamin K2. Bone mineral density (BMD), electrolyte levels, pain scores, bone metabolism levels, and adverse drug reactions were compared pre- and post-treatment. Both two treatments improved BMD, blood calcium concentrations, pain scores, and increased osteocalcin and osteoprotegerin levels. Notably, the combined rhPTH (1-34) and vitamin K2 treatment demonstrated superior efficacy in improving BMD and bone metabolism markers. Furthermore, there was no significant difference in the incidence of adverse reactions between the two groups, indicating the safety of the combined treatment. In summary, the combined therapy of rhPTH (1-34) and vitamin K2 exhibited more potent efficacy in the treatment of postmenopausal osteoporosis, more effectively enhancing BMD and bone metabolism markers than vitamin K2 alone, without a significant increase in adverse reactions.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":"33-38"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142092810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Denosumab for Management of Hypercalcemia in Primary Hyperparathyroidism. 用于治疗原发性甲状旁腺功能亢进症高钙血症的地诺单抗

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2024-12-01 Epub Date: 2024-10-11 DOI: 10.1055/a-2411-9426

Yihan Zhao, Fang Zhang, Simin Zhang, Xiaona Zhang, Leili Gao, Qian Ren, Xueyao Han, Linong Ji

{"title":"Denosumab for Management of Hypercalcemia in Primary Hyperparathyroidism.","authors":"Yihan Zhao, Fang Zhang, Simin Zhang, Xiaona Zhang, Leili Gao, Qian Ren, Xueyao Han, Linong Ji","doi":"10.1055/a-2411-9426","DOIUrl":"10.1055/a-2411-9426","url":null,"abstract":"Denosumab is a completely human monoclonal high-affinity antibody that binds to the nuclear factor kappa-B ligand (RANKL) and is widely used to treat osteoporosis. Furthermore, it can potentially lower serum calcium levels by inhibiting osteoclast activation and preventing bone calcium from being released into the blood. This review aimed to provide evidence of the efficacy and safety of denosumab in treating hypercalcemia in primary hyperparathyroidism (PHPT). PubMed and the Cochrane Library were searched for published studies that described denosumab for hypercalcemia management in PHPT. Data were extracted by two independent investigators and analyzed using SPSS 23. The risk of bias was assessed by NIH Quality Assessment Tool. In total, 161 patients with PHPT from 18 studies were included in this review. The average age was 61 (47-72) years and the highest serum calcium was 3.76 (3.11-4.20) mmol/l. We found that denosumab can effectively reduce the serum calcium level by a median reduction of 0.5 mmol/l within 3 days. Significant reduction was maintained for 14 days. The serum calcium-lowering effect weakened after one month. In conclusion, denosumab has a potential clinical value in treating hypercalcemia in patients with PHPT.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":"839-844"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Single-Center Pilot Study of Therapeutic Apheresis in Patients with Severe Post-COVID Syndrome. 重症后冠状病毒综合征患者治疗性采血的单中心试点研究

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2024-12-01 Epub Date: 2024-12-09 DOI: 10.1055/a-2445-8593

Johannes Korth, Charlotte Steenblock, Romy Walther, Mahmoud Barbir, Michael Husung, Ansgar Velthof

{"title":"A Single-Center Pilot Study of Therapeutic Apheresis in Patients with Severe Post-COVID Syndrome.","authors":"Johannes Korth, Charlotte Steenblock, Romy Walther, Mahmoud Barbir, Michael Husung, Ansgar Velthof","doi":"10.1055/a-2445-8593","DOIUrl":"10.1055/a-2445-8593","url":null,"abstract":"After the COVID-19 pandemic, many patients have reported chronic fatigue and severe post-exertional malaise, with symptoms similar to those of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The accumulation of agonistic receptor autoantibodies targeting beta-adrenergic (β1 and β2) and muscarinic (M3 and M4) neurotransmitter receptors may play a crucial role in the pathomechanism of both ME/CFS and post-COVID conditions. Therapeutic apheresis has been suggested as an effective treatment option for alleviating and mitigating symptoms in this desperate group of patients. In this single-center pilot study, we analyzed autoantibodies in a cohort of 20 post-COVID patients before and after therapeutic apheresis. Apheresis resulted in a decline of β1 or β2 adrenergic receptor antibodies in all patients. Additionally, the majority of patients experienced a concurrent reduction in symptoms such as fatigue, physical activity restrictions, myalgia, post-exertional malaise, and concentration disorders. This study clearly demonstrates an association between autoantibodies and the clinical improvement of post-COVID patients. Even if future sham-controlled trials do not show a positive outcome, extracorporeal apheresis may still be valuable for this patient group by temporarily improving microperfusion and symptoms. Success in restoring patients to work and normal life, as observed in many individuals after therapeutic apheresis, should be recognized. Therefore, we believe that extracorporeal therapeutic apheresis, as part of a multimodal treatment, should be considered an early intervention for postinfectious syndromes in selected patients.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":"56 12","pages":"869-874"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Loxenatide Alleviates High Glucose-Induced Pancreatic β-Cell Senescence via Regulating the PERK/eIF2α Pathway. 洛赛那肽通过调节 PERK/eIF2α 通路缓解高血糖诱导的胰腺β细胞衰老

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2024-12-01 Epub Date: 2024-09-27 DOI: 10.1055/a-2407-9360

Junfang Yuan, Yuzhong Wang, Defeng Wang, Han Yan, Ning Wang

{"title":"Loxenatide Alleviates High Glucose-Induced Pancreatic β-Cell Senescence via Regulating the PERK/eIF2α Pathway.","authors":"Junfang Yuan, Yuzhong Wang, Defeng Wang, Han Yan, Ning Wang","doi":"10.1055/a-2407-9360","DOIUrl":"10.1055/a-2407-9360","url":null,"abstract":"Glucagon-like peptide-1 (GLP-1) receptor agonists are effective hypoglycemic agents for type 2 diabetes mellitus (T2DM). It was reported that T2DM was implicated in pancreatic β-cell senescence. Whether loxenatide regulates cellular senescence of pancreatic β-cells is to be investigated. Our results revealed that high glucose (HG)-induced cellular senescence and elevated expression of SASP factors inhibited cell proliferation and stimulated DNA damage, which were reversed by loxenatide treatment. In addition, HG induction resulted in promoted insulin secretion and insulin synthesis of pancreatic β-cells and loxenatide treatment further strengthened these influences. In addition, loxenatide could inactivate the PERK/eIF2α signaling pathway via decreasing the levels of p-PERK and p-eIF2α in HG-induced pancreatic β-cells. Furthermore, CCT020312, an activator of the PERK/eIF2α signaling pathway, abolished loxenatide-mediated inhibiting cellular senescence, elevating cell proliferation and improving DNA damage and enhancing insulin secretion of HG-induced pancreatic β-cells. In conclusion, our results indicated that loxenatide impeded cellular senescence, promoted cell proliferation, improved DNA damage, enhanced insulin secretion and insulin synthesis of HG-induced pancreatic β-cells through modulating the PERK/eIF2α signaling pathway.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":"890-899"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142345710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: A Single-Center Pilot Study of Therapeutic Apheresis in Patients with Severe Post-COVID Syndrome. 更正：一项治疗性采血在重症后冠状病毒综合征患者中的单中心试点研究。

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2024-12-01 Epub Date: 2025-01-22 DOI: 10.1055/a-2505-6713

Johannes Korth, Charlotte Steenblock, Romy Walther, Mahmoud Barbir, Michael Husung, Ansgar Velthof

引用次数: 0

Thyroid Hormone and Diabetes Mellitus Interplay: Making Management of Comorbid Disorders Complicated. 甲状腺激素与糖尿病的相互作用：让并发症的管理变得复杂。

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2024-12-01 Epub Date: 2024-08-19 DOI: 10.1055/a-2374-8756

Ayush Chauhan, Snehal S Patel

{"title":"Thyroid Hormone and Diabetes Mellitus Interplay: Making Management of Comorbid Disorders Complicated.","authors":"Ayush Chauhan, Snehal S Patel","doi":"10.1055/a-2374-8756","DOIUrl":"10.1055/a-2374-8756","url":null,"abstract":"Insulin and thyroid hormones play important roles in our body. Insulin helps regulate the glucose level while the thyroid hormones affect various cells and tissues, metabolizing protein, lipids, and glucose. Hyperthyroidism and thyrotoxicosis are potential hazards for type 2 diabetes mellitus. There is a high prevalence of hypothyroidism being more common compared to hyperthyroidism coexisting with diabetes mellitus. Thyroid hormones affect glucose metabolism through its action on peripheral tissues (gastrointestinal tract, liver, skeletal muscles, adipose tissue, and pancreas). High-level thyroid hormone causes hyperglycemia, upregulation of glucose transport, and reduction in glycogen storage. The reverse is observed during low levels of thyroid hormone along with insulin clearance. The net result of thyroid disorder is insulin resistance. Type 2 diabetes mellitus can downsize the regulation of thyroid stimulating hormones and impair the conversion of thyroxine to triiodothyronine in peripheral tissues. Furthermore, poorly managed type 2 diabetes mellitus may result in insulin resistance and hyperinsulinemia, contributing to the proliferation of thyroid tissue and an increase in nodule formation and goiter size. Although metformin proves advantageous for both type 2 diabetes mellitus and thyroid disorder patients, other antidiabetics like sulfonylureas, pioglitazone, and thiazolidinediones may have adverse effects on thyroid disorders. Moreover, antithyroid drugs such as methimazole can weaken glycemic control in individuals with diabetes. Thus, an interplay between both endocrinopathies is observed and individualized care and management of the disorder needs to be facilitated.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":"845-858"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142004113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of the Malignancy Risk in Nodules Expanding the Thyroid Gland Capsule. 评估甲状腺囊肿结节的恶性风险

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2024-12-01 Epub Date: 2024-06-28 DOI: 10.1055/a-2356-8223

Ismail Emre Arslan, Hayri Bostan, Sema Hepşen, Pinar Akhanli, Muhammed Erkam Sencar, Erman Cakal

{"title":"Evaluation of the Malignancy Risk in Nodules Expanding the Thyroid Gland Capsule.","authors":"Ismail Emre Arslan, Hayri Bostan, Sema Hepşen, Pinar Akhanli, Muhammed Erkam Sencar, Erman Cakal","doi":"10.1055/a-2356-8223","DOIUrl":"10.1055/a-2356-8223","url":null,"abstract":"There has been an increase in the diagnosis of thyroid nodules in recent years. In addition to the well-known criteria, features that are likely to increase the risk of malignancy are in the research process. In this study, we aimed to evaluate the malignant potential of nodules that expand the thyroid capsule ultrasonographically. A total of 109 patients with thyroid capsule-expanding nodules and 288 patients with non-expanding nodules were included in the study. Demographical data, ultrasonography features, and cytology results were noted, and histopathological findings were determined in operated patients. While malignant cytology was detected in 5.5% of capsule-expanding nodules in FNAB results, this rate was 0.7% in the non-capsule expanding group (p<0.001). According to the histopathological results, the incidence of malignancy was 15.6% in the capsule-expanding nodule group, while it was 3.1% in the other group (p=0.001). As a result of logistic regression analysis, it was determined that the risk of malignancy increased by 4.44-fold (95% CI 1.4-13.8, p=0.01) in patients with capsule-expanding nodules. Other features that increased the risk of malignancy were hypoechogenicity, microcalcification, and irregular margin presence. In this study, we found that the risk of malignancy increased in nodules expanding the thyroid capsule. Based on the increasing study data on this subject, monitoring thyroid capsule expansion in nodules may take its place among the criteria for malignancy in future evaluations.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":"875-881"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Andrew Victor Schally - Nobel Prize Winner in Medicine, Legend and Pioneer in Endocrinology and a Great Friend and Supporter of the TransCampus. 安德鲁·维克多·沙利-诺贝尔医学奖得主，内分泌学的传奇人物和先驱，也是TransCampus的伟大朋友和支持者。

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2024-12-01 Epub Date: 2024-12-09 DOI: 10.1055/a-2452-0604

引用次数: 0